International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-6 doi: 10.5281/zenodo.10425382
Original Article
A Comparative Study of Topical Clindamycin Versuscombination of Topical Clindamycin and Topical Benzoyl Peroxide Gel in Evaluating Inflammatory and Non-Inflammatory Acne Counts Using the Investigator Global Assessment (IGA) Scale in Mild to Moderate Acne Vulgaris
 ,
Abstract

Background: Acne vulgaris is a common dermatological condition with significant physical and psychological impacts. This study aims to compare the efficacy of topical clindamycin versus combination of topical clindamycin and topical benzoyl peroxide gel in treating mild to moderate acne vulgaris.

Methods: A randomized, patient-blinded study was conducted over twelve months, involving 130 patients with mild to moderate acne vulgaris. Patients were treated with either clindamycin or a combination of clindamycin and benzoyl peroxide. The primary outcome was the change in inflammatory and non-inflammatory acne counts using the Investigator Global Assessment (IGA) scale.

Results: The combination therapy group showed a more significant reduction in both inflammatory and non-inflammatory acne counts compared to the clindamycin monotherapy group. By the 3rd visit, 83.33% of patients receiving combination therapy had "0 to 3" inflammatory counts, compared to 35.29% in the clindamycin group. Similarly, there was a noticeable reduction in non-inflammatory lesions in the combination therapy group.

Conclusion: Both clindamycin and benzoyl peroxide are effective in reducing acne lesions, with combination therapy demonstrating superior efficacy. The study also highlights the role of patient-specific factors in treatment response, underscoring the importance of personalized acne management strategies.

Recommended Articles
Loading Image...
Volume-4, Issue-6
Citations
2145 Views
296 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved